REDWOOD CITY, Calif., June 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced it agreed to divest YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend...
AbbVie inks immune disorder drug licensing deal with China`s FutureGen
AbbVie`s tight grip on Humira market raises concerns about biosimilars
Fresenius Kabi Usa's Generic Adalimumab-Aacf Receives Approval in US
Fresenius Kabi USA`s Idacio (adalimumab-aacf) Receives Suppl Approval in the U.S.
Republicans and Democrats on the Senate Judiciary Committee on Tuesday both acknowledged the need for further reforms on how pharma patents are reviewed and how the system functions.
SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira® REYKJAVIK, ICELAND & PARSIPPANY, NJ ” Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical...
Boehringer enlists Cigna`s Quallent to expand Humira biosimilar reach
RIDGEFIELD, Conn., May 13, 2024 /PRNewswire/ -- Boehringer Ingelheim announced an agreement with Quallent Pharmaceuticals, a private label pharmaceutical distributor, to help expand patient access to citrate-free adalimumab-adbm, Boehringer's biosimilar to Humira® (adalimumab), in the U.S.
JERSEY CITY, N.J., May 9, 2024 /PRNewswire/ -- Celltrion USA announced today that adalimumab-aaty, the company's high-concentration (100 mg/mL) and citrate-free formulation biosimilar to HUMIRA ® (adalimumab), is now available at a low wholesale acquisition cost (WAC). Adalimumab-aaty will be priced as WAC list price at an 85% discount to the current WAC list price of HUMIRA. Adalimumab-aaty is also available from Celltrion USA under the brand name YUFLYMA®, which launched in July 2023 and is available at a 5% discount to the current WAC list price of HUMIRA.